Literature DB >> 29294161

[Perioperative bleeding in a Jehovah's Witness].

S Heschl1, M Schörghuber2, W Kröll2.   

Abstract

Perioperative bleeding in Jehovah's Witnesses leaves physicians with difficult medical and ethical decisions. We report the case of a 45-year-old man, who refused to accept red blood cell concentrates by a patient directive. A postoperative bleeding occurred after removal of a transplanted kidney. Despite critically low hemoglobin (3.1 g/dl) and hematocrit (9.5%) levels, the case was managed without red blood cell transfusions. The patient showed an amazingly quick recovery and was discharged from hospital after 24 days without any sequelae.

Entities:  

Keywords:  Anemia; Blood transfusion; Jehovah’s Witnesses; Kidney transplantation; Postoperative hemorrhage

Mesh:

Substances:

Year:  2018        PMID: 29294161     DOI: 10.1007/s00101-017-0402-5

Source DB:  PubMed          Journal:  Anaesthesist        ISSN: 0003-2417            Impact factor:   1.041


  5 in total

1.  Emergency subtotal colectomy in a Jehovah's Witness with massive lower gastrointestinal bleeding: challenges encountered and lessons learned.

Authors:  Shankar R Raman; Vellore S Parithivel; John M Cosgrove
Journal:  Am J Crit Care       Date:  2011-03       Impact factor: 2.228

2.  [Legal pitfalls in emergency medicine - how is the situation in Austria?]

Authors:  H Andel; W Kröll
Journal:  Anaesthesist       Date:  2017-05       Impact factor: 1.041

Review 3.  [Perioperative management of Jehovah's Witness patients. Special consideration of religiously motivated refusal of allogeneic blood transfusion].

Authors:  O Habler; B Voss
Journal:  Anaesthesist       Date:  2010-04       Impact factor: 1.041

Review 4.  [Under scrutiny by the state prosecutor : Legal pitfalls in emergency medicine].

Authors:  P Schelling
Journal:  Anaesthesist       Date:  2016-11       Impact factor: 1.041

Review 5.  Management of adult Jehovah's Witness patients with acute bleeding.

Authors:  Kenrick Berend; Marcel Levi
Journal:  Am J Med       Date:  2009-12       Impact factor: 4.965

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.